3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
CNS
3
Sarcoma
2
Thoracic
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Renal Cell
6
Melanoma
4
Prostatic Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Kidney Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Upper Tract Urothelial Carcinoma
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
Filgrastim
10
Carboplatin
10
Ifosfamide
9
Paclitaxel
8
Peripheral Blood Stem Cell Transplantation
7
Etoposide
7
X-Rays
5
Specimen Handling
5
Phantoms, Imaging
5
Magnetic Resonance Spectroscopy
5
Thiotepa
4
Nuclear Medicine Department, Hospital
4
Melphalan
4
Cisplatin
4
Busulfan
4
Biopsy
4
pegfilgrastim
3
etoposide phosphate
3
Temozolomide
3
Granulocyte Colony-Stimulating Factor
3
tazemetostat
2
olaparib
2
larotrectinib
2
ixabepilone
2
erdafitinib
2
ensartinib
2
Vemurafenib
2
Stem Cell Transplantation
2
Mesna
2
LY3023414
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Central Nervous System Neoplasms
×
Immunotherapy
×
Genitourinary
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled